Combination and integration to redirect NK cells for cancer immunotherapy

Ying Gong

Research output: ThesisDoctoral ThesisInternal

422 Downloads (Pure)


Cancer is a disease with still a high mortality. The number of new cases is still increasing globally despite current treatments. Therefore, new therapies with high specificity and efficiency to control the progress of cancer are urgently needed in the clinic. Nowadays, new cancer treatments emerged that are based on the immune system that have achieved encouraging outcomes. Together these modalities are called tumour immunotherapy. In this current PhD thesis, we have continued our group’s previous research on developing novel approaches for cancer immunotherapies are based on natural killer (NK) cells. This research demonstrated multiple methods to enhance the anti-tumour capacities of NK cells: 1) a combination with an anti-tumour antibody, 2) introduced an activation chimeric antigen receptor (CAR), 3) CRISPR/Cas9 genetic deletion of an inhibitory signal. These NK cell combinatorial approaches are ready for scale-up to be implemented into clinical treatments to the ultimate benefit of patients.
Original languageEnglish
Awarding Institution
  • Maastricht University
  • Germeraad, Wilfred, Supervisor
  • Bos, Gerardus, Supervisor
  • Klein Wolterink, R.J.G., Co-Supervisor, External person
Award date30 Nov 2021
Place of PublicationMaastricht
Print ISBNs9789464168303
Publication statusPublished - 2021


  • cancer immunotherapy
  • natural killer cells
  • genetic modification
  • anti-tumour antibody


Dive into the research topics of 'Combination and integration to redirect NK cells for cancer immunotherapy'. Together they form a unique fingerprint.

Cite this